Mind Medicine (MindMed) (OTCMKTS:MMEDF) Trading Up 6.3% – Here’s Why
by Jessica Moore · The Cerbat GemMind Medicine (MindMed) Inc. (OTCMKTS:MMEDF – Get Free Report) shares rose 6.3% on Friday . The company traded as high as $47.01 and last traded at $44.79. 8,285,593 shares changed hands during mid-day trading, an increase of 145% from the average session volume of 3,376,665 shares. The stock had previously closed at $42.13.
Mind Medicine (MindMed) Stock Performance
The stock has a 50-day moving average price of $24.12 and a 200 day moving average price of $19.03.
About Mind Medicine (MindMed)
Mind Medicine (MindMed) is a clinical-stage biotechnology company focused on developing innovative therapies derived from psychedelic compounds to address mental health disorders and addiction. The company’s research pipeline includes programs based on LSD, psilocybin and 18-methoxycoronaridine (18-MC), targeting conditions such as anxiety disorders, attention-deficit/hyperactivity disorder (ADHD) and opioid dependence. MindMed seeks to build a portfolio of drug candidates that combine pharmacological efficacy with optimized dosing regimens and delivery methods.
Founded in 2019 and headquartered in New York City, MindMed operates research facilities in North America and Europe, collaborating with academic institutions and medical centers to advance its clinical trials.
Featured Articles
- Five stocks we like better than Mind Medicine (MindMed)
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds